MY157359A - Monoclonal antibodies capable of reacting with a plurality of influenza virus a subtypes - Google Patents

Monoclonal antibodies capable of reacting with a plurality of influenza virus a subtypes

Info

Publication number
MY157359A
MY157359A MYPI2010004341A MYPI20104341A MY157359A MY 157359 A MY157359 A MY 157359A MY PI2010004341 A MYPI2010004341 A MY PI2010004341A MY PI20104341 A MYPI20104341 A MY PI20104341A MY 157359 A MY157359 A MY 157359A
Authority
MY
Malaysia
Prior art keywords
monoclonal antibodies
subtypes
reacting
influenza
virus
Prior art date
Application number
MYPI2010004341A
Other languages
English (en)
Inventor
Burioni Roberto
Clementi Massimo
Original Assignee
Pomona Ricerca Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40293277&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY157359(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pomona Ricerca Srl filed Critical Pomona Ricerca Srl
Publication of MY157359A publication Critical patent/MY157359A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6839—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses
    • A61K47/6841—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses the antibody targeting a RNA virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4216—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-viral Ig
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
MYPI2010004341A 2008-03-17 2009-03-16 Monoclonal antibodies capable of reacting with a plurality of influenza virus a subtypes MY157359A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000204A ITTO20080204A1 (it) 2008-03-17 2008-03-17 Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a

Publications (1)

Publication Number Publication Date
MY157359A true MY157359A (en) 2016-05-31

Family

ID=40293277

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2010004341A MY157359A (en) 2008-03-17 2009-03-16 Monoclonal antibodies capable of reacting with a plurality of influenza virus a subtypes

Country Status (22)

Country Link
US (3) US9200063B2 (es)
EP (1) EP2274335B2 (es)
JP (1) JP5542118B2 (es)
KR (1) KR101605573B1 (es)
CN (1) CN102037013B (es)
AU (1) AU2009227567B2 (es)
BR (1) BRPI0909123B8 (es)
CA (1) CA2718923C (es)
DK (1) DK2274335T3 (es)
EA (1) EA027069B1 (es)
ES (1) ES2544968T5 (es)
HU (1) HUE025329T2 (es)
IL (1) IL208210A0 (es)
IT (1) ITTO20080204A1 (es)
MX (1) MX2010010120A (es)
MY (1) MY157359A (es)
NZ (1) NZ588238A (es)
PL (1) PL2274335T3 (es)
PT (1) PT2274335E (es)
SG (1) SG188890A1 (es)
WO (1) WO2009115972A1 (es)
ZA (1) ZA201006934B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITTO20070066A1 (it) 2007-01-30 2008-07-31 Pomona Biotechnologies Llc Anticorpi monoclonali anti-idiotipo mimotopi dell'antigene gp 120 di hiv
US20110038935A1 (en) 2007-12-06 2011-02-17 Marasco Wayne A Antibodies against influenza virus and methods of use thereof
ITTO20080204A1 (it) * 2008-03-17 2009-09-18 Pomona Biotechnologies Llc Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
ITTO20080398A1 (it) 2008-05-27 2009-11-28 Pomona Biotechnologies Llc Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1
JP2011528902A (ja) 2008-07-25 2011-12-01 インスティテュート・フォー・リサーチ・イン・バイオメディシン 抗ａ型インフルエンザウイルス中和抗体およびその使用
ITTO20080964A1 (it) 2008-12-22 2010-06-23 Natimab Therapeutics S R L Anticorpo monoclonale anti-hcv come medicamento per il trattamento terapeutico e la prevenzione di infezioni da hcv
EP2413962A1 (en) 2009-03-30 2012-02-08 Mount Sinai School of Medicine Influenza virus vaccines and uses thereof
US8470327B2 (en) 2009-05-11 2013-06-25 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus H3N2 and uses thereof
IT1395961B1 (it) * 2009-06-01 2012-11-02 Pomona Biotechnologies Llc Anticorpi monoclonali come medicamento per il trattamento terapeutico e/o profilattico delle infezioni da virus influenzale a (h1n1) di origine suina (s-oiv)
EP2486054A4 (en) * 2009-10-09 2013-09-11 Univ Emory RECOMBINANT ANTIBODIES AGAINST H1N1 INFLUENZA
EP2536425B1 (en) 2010-02-18 2019-06-19 Icahn School of Medicine at Mount Sinai Vaccines for use in the prophylaxis and treatment of influenza virus disease
ITTO20100237A1 (it) * 2010-03-26 2011-09-27 Pomona Biotechnologies Llc Immunoglobuline intere della classe delle igg per l'uso come medicamento antinfluenzale
EP2552485B1 (en) * 2010-03-26 2017-03-08 Pomona Ricerca S.r.l. Full-length immunoglobulins of the igg isotype capable of recognizing a heterosubtype neutralizing epitope on the hemagglutinin stem region and their use as anti-influenza medicament
ITTO20110067A1 (it) * 2011-01-26 2012-07-27 Pomona Ricerca Srl Immunoglobuline intere di isotipo igg atte a riconoscere un epitopo di neutralizzazione eterosubtipica sulla regione stelo (stem region) dell'emoagglutinina e loro uso come medicamento antinfluenzale
KR20130075732A (ko) 2010-03-30 2013-07-05 마운트 시나이 스쿨 오브 메디슨 인플루엔자 바이러스 백신 및 이의 용도
US9534042B2 (en) 2010-09-03 2017-01-03 Fujita Health University Influenza virus-neutralizing antibody and screening method therefor
EP3699286A1 (en) 2011-04-20 2020-08-26 The Trustees of the University of Pennsylvania Regimens and compositions for aav-mediated passive immunization of airborne pathogens
CN102775469B (zh) * 2011-05-12 2018-02-09 厦门大学 甲型流感病毒核衣壳蛋白的抗原表位及其用途
SI2734545T1 (sl) 2011-07-18 2019-06-28 Institute For Research In Biomedicine Protitelesa, ki nevtralizirajo virus influence A in njihova uporaba
EP2758075B1 (en) 2011-09-20 2023-05-03 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof
AU2012326025B2 (en) 2011-10-18 2017-08-31 Emory University Antibodies directed against influenza
JP6325451B2 (ja) 2011-12-02 2018-05-16 アイム・セラピューティクス・べー・フェー Ａ型インフルエンザに特異的な抗体
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
TWI657095B (zh) 2012-11-13 2019-04-21 美商建南德克公司 抗血球凝集素抗體及使用方法
AU2013362935B2 (en) 2012-12-18 2018-10-04 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
WO2014159960A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
AU2014329609B2 (en) 2013-10-02 2019-09-12 Humabs Biomed Sa Neutralizing anti-influenza A antibodies and uses thereof
WO2015175639A1 (en) 2014-05-13 2015-11-19 The Trustees Of The University Of Pennsylvania Compositions comprising aav expressing dual antibody constructs and uses thereof
AU2015289805B2 (en) 2014-07-15 2020-06-25 Humabs Biomed Sa Neutralizing anti-influenza B antibodies and uses thereof
TWI702229B (zh) 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
US10736956B2 (en) 2015-01-23 2020-08-11 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
MA48852A (fr) 2015-05-13 2020-04-01 Univ Pennsylvania Expression médiée par aav d'anticorps anti-grippaux et leurs procédés d'utilisation
DK3303384T3 (da) 2015-06-01 2021-10-18 Medimmune Llc Neutraliserende anti-influenza-bindingsmolekyler og anvendelser deraf
WO2017083627A1 (en) 2015-11-13 2017-05-18 Visterra, Inc. Compositions and methods for treating and preventing influenza
SG11201805001UA (en) 2016-01-13 2018-07-30 Medimmune Llc Method of treating influenza a
WO2017218624A1 (en) 2016-06-15 2017-12-21 Icahn School Of Medicine At Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
SG10201913833PA (en) 2017-02-28 2020-03-30 Univ Pennsylvania Influenza vaccines based on aav vectors
SG11201907714UA (en) 2017-02-28 2019-09-27 Univ Pennsylvania Adeno-associated virus (aav) clade f vector and uses therefor
US11254733B2 (en) 2017-04-07 2022-02-22 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
CN112334478A (zh) * 2018-06-11 2021-02-05 葛兰素史克消费保健（美国）控股有限责任公司 用于快速甲型流感诊断测试的抗体对
KR20200060969A (ko) * 2018-11-23 2020-06-02 (주)셀트리온 인플루엔자 바이러스 질환을 치료하기 위한 투여 요법
AU2020248404A1 (en) 2019-03-25 2021-09-30 Visterra, Inc. Compositions and methods for treating and preventing influenza
US20240024507A1 (en) 2020-12-01 2024-01-25 The Trustees Of The University Of Pennsylvania Novel compositions with tissue-specific targeting motifs and compositions containing same
KR20240011714A (ko) 2021-04-27 2024-01-26 제너레이션 바이오 컴퍼니 치료용 항체를 발현하는 비바이러스성 dna 벡터 및 이의 용도
WO2023177655A1 (en) 2022-03-14 2023-09-21 Generation Bio Co. Heterologous prime boost vaccine compositions and methods of use
CN115724952B (zh) * 2022-07-13 2023-10-31 扬州大学 一种靶向甲型流感病毒保守线性b细胞表位的广谱单克隆抗体及其应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA836080B (en) 1982-08-23 1984-04-25 Scripps Clinic Res Broad spectrum influenza antisera
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US6812024B2 (en) 1987-03-16 2004-11-02 Mcgready Roland Keith Anti-paratopic antibody as an immunogen
US5245015A (en) 1991-04-26 1993-09-14 Tanox Biosystems, Inc. Monoclonal antibodies which neutralize HIV-1 through reaction with a conformational epitope in vitro
WO1992015885A1 (en) 1991-03-11 1992-09-17 Idec Pharmaceuticals Corporation Methods for selecting antibody reagents; anti-idiotype antibodies; and aids vaccine formulations
ATE255902T1 (de) 1992-03-09 2003-12-15 San Diego Regional Cancer Ct Ein anti-idiotypischer antikörper und seine verwendung in der diagnose und therapie von hiv- verwandten krankheiten
EP0621339B1 (en) 1992-09-17 2001-10-24 Takara Shuzo Co. Ltd. Immunogenic human influenza A virus haemagglutinin polypeptides
GB9221654D0 (en) * 1992-10-15 1992-11-25 Scotgen Ltd Recombinant human anti-cytomegalovirus antibodies
JP2996864B2 (ja) * 1994-03-30 2000-01-11 寳酒造株式会社 抗体可変領域ｄｎａ
US6057421A (en) 1994-11-30 2000-05-02 Immpheron, Inc. Variable heavy and light chain regions of murine monoclonal antibody 1F7
CN101088561A (zh) 1998-07-21 2007-12-19 展马博联合股份有限公司 抗丙型肝炎病毒抗体及其用途
WO2002055560A2 (en) 2000-12-01 2002-07-18 The Gouvernment Of The United States Of America, As Represented By The Secretary Department Of Health And Human Services Monoclonal antibodies specific for the e2 glycoprotein of hepatitis c virus and their use in the diagnosis, treatment, and prevention of hepatitis c
FR2817869B1 (fr) * 2000-12-07 2005-01-14 Technopharm Anticorps monoclonal humain dirige contre le virus influenza ou un fragment de celui-ci
US6768004B2 (en) 2001-01-11 2004-07-27 Mueller Sybille Nucleotide sequences encoding variable regions of heavy and light chains of monoclonal antibody 1F7, an anti-idiotypic antibody reactive with anti-HIV antibodies
US6964199B2 (en) 2001-11-02 2005-11-15 Cantocor, Inc. Methods and compositions for enhanced protein expression and/or growth of cultured cells using co-transcription of a Bcl2 encoding nucleic acid
JP4495969B2 (ja) 2002-01-17 2010-07-07 ポリマン サイエンティフィック イミューンバイオロジッシュ フォーシュング ゲゼルシャフト ミット ベシュレンクテル ファフツング Ｈｉｖ−１中和抗体を誘導する抗イディオタイプ抗体
ITRM20020049A1 (it) 2002-01-30 2003-07-30 Biostrands S R L Frammenti fab di anticorpi monoclonali umani diretti contro la glicoproteina e2 di hcv e dotati di potere neutralizzante in vitro.
US20080014205A1 (en) * 2006-05-15 2008-01-17 Lawrence Horowitz Neutralizing Antibodies to Influenza Viruses
WO2008028946A2 (en) 2006-09-07 2008-03-13 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
AU2007295073A1 (en) 2006-09-15 2008-03-20 Fraunhofer Usa, Inc. Influenza antibodies, compositions, and related methods
ITTO20070066A1 (it) 2007-01-30 2008-07-31 Pomona Biotechnologies Llc Anticorpi monoclonali anti-idiotipo mimotopi dell'antigene gp 120 di hiv
AU2008300516A1 (en) 2007-09-20 2009-03-26 Bracco Imaging Spa Method for the preparation of new oligoclonal antibodies
ITTO20080204A1 (it) * 2008-03-17 2009-09-18 Pomona Biotechnologies Llc Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
ITTO20080398A1 (it) 2008-05-27 2009-11-28 Pomona Biotechnologies Llc Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1
ITTO20080964A1 (it) 2008-12-22 2010-06-23 Natimab Therapeutics S R L Anticorpo monoclonale anti-hcv come medicamento per il trattamento terapeutico e la prevenzione di infezioni da hcv
IT1395961B1 (it) 2009-06-01 2012-11-02 Pomona Biotechnologies Llc Anticorpi monoclonali come medicamento per il trattamento terapeutico e/o profilattico delle infezioni da virus influenzale a (h1n1) di origine suina (s-oiv)
EP2552485B1 (en) 2010-03-26 2017-03-08 Pomona Ricerca S.r.l. Full-length immunoglobulins of the igg isotype capable of recognizing a heterosubtype neutralizing epitope on the hemagglutinin stem region and their use as anti-influenza medicament

Also Published As

Publication number Publication date
EP2274335B8 (en) 2015-06-17
EP2274335A1 (en) 2011-01-19
CN102037013B (zh) 2015-01-28
ES2544968T5 (es) 2022-11-22
ZA201006934B (en) 2011-12-28
KR20100126810A (ko) 2010-12-02
US9200063B2 (en) 2015-12-01
ITTO20080204A1 (it) 2009-09-18
EP2274335B1 (en) 2015-05-13
US20160060325A1 (en) 2016-03-03
CA2718923A1 (en) 2009-09-24
EP2274335B2 (en) 2022-07-27
WO2009115972A1 (en) 2009-09-24
IL208210A0 (en) 2010-12-30
HUE025329T2 (en) 2016-02-29
SG188890A1 (en) 2013-04-30
MX2010010120A (es) 2010-12-02
AU2009227567B2 (en) 2014-06-26
ES2544968T3 (es) 2015-09-07
EA201071087A1 (ru) 2011-04-29
AU2009227567A1 (en) 2009-09-24
KR101605573B1 (ko) 2016-03-22
EA027069B1 (ru) 2017-06-30
US20110014187A1 (en) 2011-01-20
CN102037013A (zh) 2011-04-27
BRPI0909123B1 (pt) 2020-12-01
DK2274335T3 (en) 2015-08-17
PL2274335T3 (pl) 2015-10-30
JP2011517403A (ja) 2011-06-09
JP5542118B2 (ja) 2014-07-09
NZ588238A (en) 2012-08-31
PT2274335E (pt) 2015-09-18
US20160200801A1 (en) 2016-07-14
BRPI0909123A2 (pt) 2019-02-26
BRPI0909123B8 (pt) 2021-06-01
US9587011B2 (en) 2017-03-07
US9598482B2 (en) 2017-03-21
CA2718923C (en) 2020-07-07

Similar Documents

Publication Publication Date Title
MY157359A (en) Monoclonal antibodies capable of reacting with a plurality of influenza virus a subtypes
EA201071365A1 (ru) Моноклональные антитела, имеющие гомоподтип кросс-нейтрализующих свойств против вируса гриппа а подтипа н1
MX2021007679A (es) Anticuerpos humanos para hemaglutinina de influenza.
CY1119284T1 (el) ΣΩΜΑΤΙΔΙΑ ΠΑΡΟΜΟΙΑ ΜΕ ΙΟ ΓΛΥΚΟ-ΠΡΩΤΕΪΝΗΣ ΛΥΣΣΑΣ (VLPs)
WO2012021786A3 (en) Anti-hemagglutinin antibody compositions and methods of use thereof
EA032929B1 (ru) Нейтрализующее вирус иммунодефицита человека антитело и способы его применения
WO2007095318A3 (en) Influenza antigens, vaccine compositions, and related methods
WO2008039267A3 (en) Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions
BR112014004860A2 (pt) composições de anticorpo contra vírus da influenza
WO2009026397A3 (en) Prophylactic and therapeutic influenza vaccines, antigens, compositions, and methods
MX2013004897A (es) Anticuerpos y composiciones anti-her3.
MX352338B (es) Anticuerpos neutralizantes del virus de la influenza a y usos de estos.
EA201300256A1 (ru) Антитела к рецептору эпидермального фактора роста-3 (her3)
WO2012027365A3 (en) Targeted multi-epitope dosage forms for induction of an immune response to antigens
WO2013059524A3 (en) Antibodies directed against influenza
CR20130632A (es) El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapéutico
TR201802380T4 (tr) Benzonaftiridin içeren aşılar.
EA201391515A1 (ru) Инактивированная вакцина вируса денге
TR201903026T4 (tr) S100a4 anti̇korlari ve bunlarin terapöti̇k kullanimlari.
PL2575873T3 (pl) Zatężanie i liofilizacja antygenów szczepionkowych grypy
EA201290956A1 (ru) Вакцина против вич
EA201290897A1 (ru) Вакцины для пандемического гриппа
PL2575872T3 (pl) Zatężanie antygenów szczepionkowych grypy bez liofilizacji
MX2015013304A (es) Vacunas de nucleoproteina de la influenza.
BR112012029633A8 (pt) Vetores do parapoxvírus contendo antígeno do vírus da raiva.